Targeted treatment slows progression of rare connective tissue tumor
In a phase three clinical trial, a drug called sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment, a significant increase in progression-free survival compared ...
Dec 19, 2018
0
13